BCMA-specific CAR-T cells for R/R multiple myeloma

Kenneth C. Anderson - Multiple myeloma cured in 2030: what are the next steps?Подробнее

Kenneth C. Anderson - Multiple myeloma cured in 2030: what are the next steps?

Bispecific Monoclonal Antibodies and CAR T-Cell Therapy in Multiple Myeloma, Omar Nadeem, MDПодробнее

Bispecific Monoclonal Antibodies and CAR T-Cell Therapy in Multiple Myeloma, Omar Nadeem, MD

CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhDПодробнее

CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhD

First-in-human: BCMA CAR-T plus gamma secretase inhibitor in R/R myelomaПодробнее

First-in-human: BCMA CAR-T plus gamma secretase inhibitor in R/R myeloma

Natalie Callander, MD, Discusses BCMA CAR T Cell Therapy for Multiple MyelomaПодробнее

Natalie Callander, MD, Discusses BCMA CAR T Cell Therapy for Multiple Myeloma

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T the...Подробнее

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T the...

Relapsed Therapy and Clinical Trials - RCW Pacific NWПодробнее

Relapsed Therapy and Clinical Trials - RCW Pacific NW

Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Pts w/RR Multiple MyelomaПодробнее

Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Pts w/RR Multiple Myeloma

Top Doctor & Patient Talk Game Changing Cancer Treatments: How Close is a Cure? (Multiple Myeloma)Подробнее

Top Doctor & Patient Talk Game Changing Cancer Treatments: How Close is a Cure? (Multiple Myeloma)

Updated Results from CARTITUDE-1: Phase 1b/2Study of Cilta-Cel in Pts With RR Multiple MyelomaПодробнее

Updated Results from CARTITUDE-1: Phase 1b/2Study of Cilta-Cel in Pts With RR Multiple Myeloma

Future of BCMA-Targeted Therapies in Multiple MyelomaПодробнее

Future of BCMA-Targeted Therapies in Multiple Myeloma

Best of ASH 2019Подробнее

Best of ASH 2019

CAR-T Cells: Poseida Therapeutics - Matt SpearПодробнее

CAR-T Cells: Poseida Therapeutics - Matt Spear

B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager CC-93269 in Patients with RR Multiple MyelomaПодробнее

B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager CC-93269 in Patients with RR Multiple Myeloma

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple MyelomaПодробнее

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple MyelomaПодробнее

Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma

How to decide between bispecific antibodies or CAR T-cell therapiesПодробнее

How to decide between bispecific antibodies or CAR T-cell therapies

Future Therapies in Multiple MyelomaПодробнее

Future Therapies in Multiple Myeloma

ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa resultsПодробнее

ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa results

Ongoing Myeloma CareПодробнее

Ongoing Myeloma Care